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ABSTRACT  
Understanding the physiological mechanisms by which common variants predispose to type 2 
diabetes requires large studies with detailed measures of insulin secretion and sensitivity. 
Here we performed the largest genome-wide association study of first phase insulin secretion, 
as measured by intravenous glucose tolerance tests, using up to 5,567 non-diabetic 
individuals from 10 studies. We aimed to refine the mechanisms of 178 known associations 
between common variants and glycaemic traits and identify new loci. Thirty type 2 diabetes, 
or fasting glucose raising, alleles were associated with a measure of first phase insulin 
secretion at P<0.05, and provided new evidence, or the strongest evidence yet, that insulin 
secretion, intrinsic to the islet cells, is a key mechanism underlying the associations at the 
HNF1A, IGFBP2, KCNQ1, HNF1B, VPS13C/C2CD4A, FAF1, PTPRD, AP3S2, KCNK16, 
MAEA, LPP, WFS1 and TMPRSS6 loci. The fasting glucose raising allele near PDX1, a 
known key insulin transcription factor, was strongly associated with lower first phase insulin 
secretion but has no evidence for an effect on type 2 diabetes risk. The diabetes risk allele at 
TCF7L2 was associated with a stronger effect on peak insulin response than on C-peptide-
based insulin secretion rate, suggesting a possible additional role in hepatic insulin clearance 
or insulin processing. In summary, our study provides further insight into the mechanisms by 
which common genetic variation influences type 2 diabetes risk and glycaemic traits. 
 
  
Common genetic variants associated with type 2 diabetes are more likely to be associated 
with insulin secretion than insulin resistance (1). Studies of genetic variation and insulin 
secretion have been largely limited to fasting glucose or oral glucose tolerance test (OGTT)-
based measures of beta-cell function and insulin secretion (2; 3). Oral-based measures of 
insulin secretion do not distinguish between mechanisms involving gut hormone signaling, 
e.g. incretin pathways, and mechanisms intrinsic to islet cell function or mass.  
Compared to OGTT-based measures, intravenous-based measures provide a more accurate 
measure of first phase insulin secretion, with initial release of insulin peaking in the first five 
to ten minutes following glucose stimulation. Intravenous measures include the intravenous 
glucose tolerance test (IVGTT) and hyperglycaemic clamp. Family studies have shown that 
first phase insulin response, as measured by IVGTT is one of the most highly heritable 
glycaemic measures (4-9), but genetic studies of intravenous-based measures of insulin 
secretion have examined limited numbers of variants or been performed in single studies (8; 
10-14) with the exception of a recent meta-analysis performed in Hispanic Americans (15).  
Two studies have examined the effects of known type 2 diabetes variants in large meta-
analyses of studies with OGTT data. A study of 23,443 individuals with OGTT-based 
measures of insulin secretion and insulin resistance, with a subset of 4,180 individuals with 
clamp-based measures of insulin resistance, examined 36 known type 2 diabetes variants. 
This study classified 16 variants into groups: nine were labelled as “beta-cell”, two as 
“hyperglycaemia”, four as “insulin resistance” and one as “insulin processing” (based on 
proinsulin measures) (2). This analysis left 20 variants as “unclassified” which may include 
those that do not operate through these mechanisms as defined, or may reflect a lack of power 
to distinguish mechanisms when the type 2 diabetes risk effect is relatively weak. A second 
study performed a six-study genome-wide association study (GWAS) meta-analysis of 
OGTT-based measures of insulin secretion including the corrected insulin response (CIR; 
insulin response corrected to glucose at 30 mins during an OGTT) (3). This study provided 
genome-wide data from 10,831 individuals and identified a signal in GRB10 but otherwise 
did not identify any variants not previously identified as type 2 diabetes variants. 
Here we performed a meta-analysis based GWAS of intraveneous-based measures of glucose 
stimulated insulin secretion. We used several measures of first phase insulin secretion with 
two aims - first, to refine the underlying physiology of known type 2 diabetes and glycaemic 
trait variants; second, to identify novel variants associated with first phase insulin secretion. 
Our study provides an advance to previous studies in several ways – first, it is the largest 
GWAS meta-analysis of intraveneous-based measures of glucose stimulated insulin 
secretion,; second, we used imputation from the 1000 Genomes Project to capture a wider 
range of genetic variation than previous GWAS of glycaemic traits, and third, we focused on 
characterizing the most recent lists of known type 2 diabetes and glycaemic trait variants. 
Using more than 5,500 individuals with intraveneous measures of first phase insulin secretion 
we show that most variants previously associated with insulin secretion, as measured by 
OGTT, operate through a primary islet cell-based mechanism and we provide new insight 
into the mechanisms of several variants where previous data had been unclear.  
 
 
RESEARCH DESIGN AND METHODS 
Study samples 
The meta-analysis consisted of a total of 10 studies and a maximum of 5,567 individuals, 
with the full number available depending on the phenotype. These studies represented several 
different ethnic groups, with 3 studies of 2,346 Hispanic (IRASFS (16), TRIPOD (17), 
BETAGENE (18)), 6 studies of 2,900 individuals of European ancestry (EUGENE2 (19), 
RISC (20), Hyperglycemic clamp consortium (HCC) (13), YOUTH92 (21), FAMILY (21) 
and FUSION (22)) and one study of 332 Pima Indians (23). All studies were genotyped with 
a GWAS chip except the 413 HCC participants and a subset of 328 of 554 individuals from 
the FUSION study who were typed with the Metabochip (24). Full descriptive characteristics, 
study design, sample size, sample quality control (QC) and intravenous measurement 
techniques for studies included are provided in Supplementary Tables 1-3. All participants 
provided written informed consent and the studies were approved by the respective Local 
Research Ethics committees or Institutional Review Boards. 
 
Phenotypes 
The ten studies each used a version of the IVGTT test. FUSION, Youth92, FAMILY and 
TRIPOD used tolbutamide-modified IVGTTs, IRASFS and BETAGENE insulin-modified 
IVGTTs. In the RISC study, the IVGTT was conducted at the end of an isoglycemic clamp as 
previously reported (25). 
 
In the HCC study, participants underwent a hyperglyceamic clamp after an overnight fast. 
After the priming glucose bolus, blood glucose was measured at 2 to 2.5 minute intervals and 
kept constant at 10 mmol/l for at least two hours via continuous variable glucose infusions 
(13).  
Peak insulin response 
Peak insulin response was measured as peak insulin minus baseline insulin. The peak insulin 
time point was determined for each study, according to the time point having the highest 
average insulin value across all individuals. 
 
Acute insulin response 
Acute insulin response (AIR) was measured as the incremental area under the insulin curve 
during the first 10 minutes, or if a measure at 10 minutes was not available, during the first 8 
minutes, using the trapezium equation (26), with a minimum of insulin values at 0, 2, 4, 6, 
and 8 minutes during the IVGTT. Incremental insulin was calculated by subtracting the 
fasting insulin level. 
 
Insulin secretion rate 
Insulin secretion rate (ISR) was estimated from measured serum C-peptide concentrations at 
0,2,4,6,8 (RISC) and 0, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 (FAMILY) minutes, using the 
ISEC software (27; 28), which calculates the secretion rate based on predefined C-peptide 
kinetic parameters from each individual’s weight, height, age, sex and clinical status (glucose 
tolerance and obesity status) determined in a population-based study (29; 30). ISR provides 
an estimate of the rate of insulin secretion prior to hepatic insulin clearance.  
 
Insulin sensitivity.  
We used the MINMOD software (31) to calculate insulin sensitivity or a method suitable to 
the study (e.g. for Hyperglycaemic clamps see t’Hart et al. (13)). 
 
Disposition index 
Disposition index (DI) was calculated as the product of AIR and insulin sensitivity index 
calculated using the MINMOD software (31). DI differs from peak insulin response and AIR 
because it is not a pure test of insulin secretion but takes into account the level of background 
insulin resistance. 
 
Oral glucose tolerance test measures of insulin secretion as a comparison 
Corrected insulin response (CIR) was based on oral glucose tolerance tests. To compare 
IVGTT-based results to OGTT-based results we calculated the CIR in a subset of 2,523 
individuals from five of our studies. Calculation was the same as that used and described by 
Prokopenko et al. : Corrected Insulin Response (CIR) = (100 x insulin at 30 min)/(glucose at 
30 min x (glucose at 30 min–3.89)) (3).  
 
Genotyping and imputation 
Genotyping and imputation within studies  
Details on the genotyping platform used and genotype quality control procedures employed 
for each study are presented in Supplementary Table 3. All GWAS cohorts were genotyped 
using commercially available Affymetrix (Affymetrix, Inc., Santa Clara, CA, USA), or 
Illumina (Illumina, Inc. San Diego, CA, USA) genotyping arrays. To facilitate meta-analyses 
for each trait, studies performed genotype imputation using MACH (32), MINIMAC (33), or 
IMPUTE (34) to impute up to a common set of variants. All studies (except the Pima study) 
imputed up to ~39M SNPs and indels from 2184 haplotypes available from the 1000 
Genomes Project Phase 1 - version 3 (35)). Due to the relative difference in ancestry between 
the Pima cohort and the samples within the 1000 Genomes reference panel, imputation in 
Pima was based on 532 haplotypes derived from whole-genome sequencing efforts within the 
Pima study. 
 Metabochip genotyping 
Additional studies genotyped on the Illumina Metabochip without subsequent imputation but 
with available phenotype data were also incorporated into the meta-analysis. Details of these 
studies can be found in Supplementary Tables 1-3. 
 
Statistical analysis 
Phenotype Transformations 
Each trait was adjusted for age, sex, and study specific covariates as necessary 
(Supplementary Table 2) by adding them to a regression model and using the residuals as 
the phenotype. We then inverse normalized this residualised phenotype to create a normal 
distribution. This process is important to reduce false positive results when testing 1000s of 
rarer variants. Analyses were repeated adjusting for BMI and insulin sensitivity. To account 
for population stratification, studies also adjusted for principal components or if running 
association testing outside of a linear-mixed model framework.  
 
Association analysis 
Additive association analysis for each trait was carried out using MACH2QTL (32), SOLAR 
(for IRASFS) or using linear mixed models as implemented in EMMAX (36), GEMMA (37) 
or QTassoc (38) (Supplementary Table 3). For each trait and adjustment combination, we 
performed a fixed effects meta-analysis based on standard errors, as implemented in Metal 
[http://csg.sph.umich.edu/abecasis/Metal].  We applied a variant minor allele count (MAC) 
filter of MAC>5 and genomic control correction to the input files prior to meta-analysis. 
Variants with a meta-analysis P-value <5×10-8 were considered to be genome-wide 
significant. All genome-wide statistics are available on our website (url: 
http://www.t2diabetesgenes.org/data/). 
 
Selection of known variants and previous traits  
Type 2 diabetes 
We selected 76 variants identified by GWAS as associated with type 2 diabetes. For 
European studies these were based on a GWAS+Metabochip meta-analysis of 34,840 cases 
and 114,981 controls (39) and for non-Europeans this included variants at GWAS 
significance across a trans-ethnic study meta-analysis of 26,488 cases and 83,964 controls 
(40). 
 
Glycaemic and insulin related traits 
We selected variants representing 65 signals listed in the supplementary or main tables of 
Prokopenko et al. (3) as associated with a glycaemic or insulin related trait, including fasting 
glucose, fasting insulin, 2-hour insulin, HbA1C, and proinsulin. We also selected an 
additional 5 variants associated with fasting glycaemic traits identified by an earlier meta-
analysis that fell 250kb outside of the 65 signals (41). 
 
  
RESULTS 
Several variants are associated with intravenous-based measures of first phase insulin 
secretion at genome-wide significance, including MTNR1B and CDKAL1. 
Results are represented in tables 1-5 and figures 1-4. The two strongest association signals 
represented known type 2 diabetes loci, those in or near MTNR1B and CDKAL1 (Table 1). 
The known signal at MTNR1B was associated with peak insulin response (P=1.3×10-24), AIR 
(P=3.7×10-21) and DI (P=3.3×10-17), and CDKAL1 with peak insulin response (P=1.5×10-12) 
and AIR (P=1.5×10-9). The peak insulin and AIR results were very similar after adjusting for 
BMI and/or SI (Supplementary Table 4). In addition, we identified a few novel genome-
wide associations that require further validation and replication - these associations were 
either rare variants (REG3G), only present in a specific ethnic group (CHST1) or sensitive to 
covariates used (BLVRA/MRPS24) (Supplementary Table 5). We tested these novel variants 
for an association with type 2 diabetes in the DIAbetes Genetics Replication and Meta-
analysis (DIAGRAM) GWAS (40) but none of the SNPs were associated with type 2 diabetes 
at P<0.05.  
 
Twenty-one known type 2 diabetes risk alleles are associated with lower first phase insulin 
response 
Of 76 type 2 diabetes known risk alleles, 21 were associated (at P<0.05) with reduced first 
phase insulin secretion as measured by peak insulin response or acute insulin response (17 
variants were associated with both peak insulin and AIR at P<0.05) (Table 1). Peak Insulin 
and AIR associations tended to be very similar for all variants (Table 1). This number of risk 
alleles associated with reduced insulin secretion at P<0.05 is far more than the 2-3 expected 
by chance. Three additional type 2 diabetes risk alleles were associated with higher first 
phase insulin response and these are discussed below [NOTCH2, PPARG and GCC1]. Results 
were similar when adjusting for BMI and insulin sensitivity (Supplementary Table 4). 
These 21 variants included 10 previously classified as having a clear role in insulin secretion 
- eight were previously classified as “beta-cell”, one as “hyperglycaemia” (MTN1RB) and one 
as “insulin processing” (ARAP1/STARD10) (2). We did not detect any evidence that the 
variant previously labelled as “beta-cell” in the THADA gene was associated with first phase 
insulin response. We were not able to account for the potential parent of origin effect at 
THADA (42), but neither were the previous largest OGTT-based studies. Of the eleven other 
variants we detected, those in the HNF1A, IGFBP2, KCNQ1 genes had previously been 
associated with at least one measure of insulin secretion or fasting glucose, and our data now 
strengthens the evidence that these variants increase type 2 diabetes risk through an insulin 
secretory mechanism including lower first phase insulin response. Our findings provide new 
evidence that type 2 diabetes variants in the loci labelled as in or near the HNF1B, 
VPS13C/C2CD4A, FAF1, PTPRD, AP3S2, KCNK16, MAEA and LPP genes alter type 2 
diabetes risk through mechanisms that include first phase insulin secretion. Although none of 
these eight reached Bonferroni corrected levels of significance, we would only expect 2-3 of 
76 type 2 diabetes risk alleles to be associated with lower insulin secretion at P<0.05, 
suggesting most of these eight variants operate through insulin secretion mechanisms (Table 
1).    
 
Six variants associated with higher fasting glucose but not type 2 diabetes, are associated 
with lower first phase insulin secretion. 
We next examined 70 known variants associated with intermediate glycaemic traits. These 
traits consisted of those analysed by the Meta-Analysis of Glucose and Insulin Consortium 
(MAGIC) and included fasting glucose and insulin, proinsulin, HbA1c, and 2-hour post-
OGTT glucose levels. These variants partially overlap those associated with type 2 diabetes.  
We identified 6 variants not in the type 2 diabetes list where the fasting glucose raising allele 
was associated with first phase insulin secretion before (Table 2) and after correcting for 
BMI and insulin sensitivity (Supplementary Table 6). Fasting glucose raising alleles in or 
near the PDX1, DNLZ, CRY2, GLIS3, PROX1 and ADRA2A genes were associated with 
lower first phase insulin secretion at P<0.05. We next examined published data from the 
DIAGRAM consortium to establish whether or not these alleles were associated with type 2 
diabetes but had not reached genome-wide significance – only the allele at PDX1 was not 
nominally associated with type 2 diabetes (P>0.05) in Morris et al. (39). All five of the other 
alleles associated with higher fasting glucose and lower first phase insulin were associated 
with a higher risk of type 2 diabetes with P-values of 0.03 (CRY2, Odds ratio (OR) 1.03), 
0.001 (ADRA2A OR 1.06), 0.0001 (GLIS3 OR 1.04), 0.0001 (DNLZ OR 1.06) and 1×10-7 
(PROX1 OR 1.06) (39).  
 
Ten known type 2 diabetes or glycaemic trait alleles are associated with lower insulin 
secretion rate 
For a subset of 1,268 non-diabetic individuals we had a measure of insulin secretion rate by 
C-peptide deconvolution (27; 30). For ten known variants, the type 2 diabetes or glycaemic 
trait risk allele was associated with lower insulin secretion rate at P<0.05. These analyses 
highlighted two variants that had no clear underlying physiological profile based on previous 
OGTT data or our own peak insulin response or AIR analyses – those in WFS1 and 
TMPRSS6 (Table 3). Of these ten variants previously associated with a glycaemic trait and 
associated with insulin secretion rate in our study, two were not known type 2 diabetes 
variants – those in TMPRSS6 (HbA1C raising allele associated with lower ISR) and PDX1 
(fasting glucose raising allele associated with lower ISR). The TMPRSS6 allele, like the 
PDX1 allele, was not nominally associated with type 2 diabetes in the DIAGRAM study 
(P>0.05). 
 
Sixteen variants where the type 2 diabetes risk allele is apparently paradoxically associated 
with higher insulin secretion or insulin secretion rates. 
We identified sixteen variants with apparently paradoxical effects on type 2 diabetes risk, 
glycaemic traits, and first phase insulin secretion or insulin secretion rate. These included 
three (PPARG, FTO, TET2) with known primary effects on insulin resistance (43) or BMI 
and three (ARAP1, PCSK1, MADD) (44) with known primary effects on proinsulin. Whilst 
the effects on insulin secretion were similar when correcting for insulin resistance and BMI 
the associations with disposition index tended to be weaker (Tables 4 and 5).  
 
 
DISCUSSION 
By performing a large genome-wide association study of first phase IVGTT-based insulin 
secretion we provide new insights into the likely mechanisms by which some of the known 
type 2 diabetes and glycaemic trait variants affect glucose homeostasis. Our results 
complement those from OGTT-derived measures of insulin secretion and emphasize the need 
to consider first phase, second phase and C-peptide derived measures of insulin secretion as 
well as insulin resistance when considering the likely function of type 2 diabetes associated 
alleles. We provide details of 178 previously described associations in supplementary table 8. 
We did not identify any robust associations between new variants and IVGTT-based 
measures of insulin secretion and so we focus this discussion on the known variants. The lack 
of novel variants is perhaps not surprising given the large studies of type 2 diabetes 
performed and relative power, and the likelihood that any variant with a strong effect on first 
phase insulin secretion is likely to have been associated with type 2 diabetes, or an OGTT-
based measure of insulin secretion. Previous family studies have also shown strong genetic 
overlaps between OGTT-derived CIR and IVGTT-derived AIR (45).  
 
Known type 2 diabetes risk alleles are associated with lower first phase insulin secretion in 
response to IV glucose. 
We found that 21 of the alleles previously associated with higher type 2 diabetes risk are also 
associated with lower insulin secretion during IVGTT at P<0.05. Associations were similar 
with disposition index, which corrects for insulin sensitivity. Those with the strongest effects, 
and the only ones reaching genome-wide significance, were those in or near the MTNR1B and 
CDKAL1 genes. In addition to classifications based on OGTT-derived measures (2), we can 
now also classify a number of previously unclassified loci as being involved in beta-cell 
function. These include IGF2BP2, C2CD4A, FAF1, PTPRD, AP3S2, NF1B, MAEA, 
KCNK16, and LPP. Of the nine variants previously labeled as “beta-cell” by Dimas et al., 
eight were associated with first phase insulin secretion, the exception being that in the 
THADA gene. Based on the analysis of Dimas et al., this variant is more likely to operate on 
fasting glucose rather than stimulated glucose tolerance. 
A common allele upstream of PDX1 is associated with higher fasting glucose and lower first 
phase insulin secretion but not type 2 diabetes. 
We identified six alleles that were associated with lower first phase insulin secretion that 
were previously associated with higher fasting glucose levels but were not associated, at 
genome-wide significance, with type 2 diabetes risk. These include those in or near PDX1, 
DNLZ, CRY2, GLIS3, PROX1 and ADRA2A genes. Five of these six variants are nominally 
associated with type 2 diabetes risk in the expected direction. The exception is the allele 
~6.6kb upstream of PDX1, a gene in which mutations cause maturity onset diabetes of the 
young (46). This allele has the third strongest association with first phase insulin secretion in 
our study, after those in MTNR1B and CDKAL1, and ahead of those in known type 2 diabetes 
loci such as TCF7L2, SLC30A8, IGF2BP2, CDKN2A/B and HHEX/IDE, but was not 
associated with type 2 diabetes in the most recent, multi-ethnic, type 2 diabetes study of 
26,488 cases and 83,964 controls. One explanation for this apparently paradoxical association 
is that the PDX1 allele causes a stable resetting of glucose tolerance but does not lead to 
deterioration in beta cell function, as is seen in MODY2. We also note that it is not associated 
with oral-based measures of insulin secretion (3). 
Variants with apparently paradoxical effects on type 2 diabetes risk, glycaemic traits and 
first phase insulin secretion.  
We identified 16 variants with an apparently paradoxical effect on at least one measure of 
insulin secretion and type 2 diabetes risk – the type 2 diabetes risk allele was associated with 
higher insulin secretion. Many of these associations were much weaker when using 
disposition index rather than peak insulin or acute insulin response, suggesting the 
association with higher insulin secretion is a compensatory mechanism for higher background 
insulin resistance (FTO, PPARG) (43) or less efficient insulin processing (MADD, ARAP1, 
PSCK1) (44). The exceptions were the alleles in GRB10 and G6PC2, where correcting for 
insulin resistance or using disposition index did not appreciably weaken the association. At 
both these loci, previous studies have noted the paradoxical associations between the allele 
associated with higher fasting glucose and higher OGTT-based insulin secretion (3). It was 
also previously shown that the effect of the G6PC2 gene was dependent on glycaemia which 
may explain these apparent paradoxical results and suggest that effects of hyperglycemia may 
override genetic effects observed in healthy volunteers (47). 
 
Known type 2 diabetes or glycaemic trait alleles associated with lower insulin secretion rate 
For a subset of 1,268 non-diabetic individuals we had a measure of insulin secretion rate by 
C-peptide deconvolution, a measure of insulin secretion that accounts for hepatic insulin 
clearance (29; 30). Eighteen known variants were nominally associated with insulin secretion 
rate at P<0.05 – 10 where the type 2 diabetes or glycaemic trait risk allele was associated 
with lower insulin secretion rate, and 8 where the risk allele was associated with higher 
insulin secretion rate.  These analyses highlighted two variants that had no clear underlying 
physiological profile based on previous data or our own peak insulin response or AIR 
analyses, those in WFS1 and TMPRSS6, although one large study had shown the WFS1 allele 
as associated with oral-based measures of insulin secretion (48). The statistical confidence of 
these associations was not strong and further studies are needed to confirm them. The 
diabetes risk alleles associated with higher insulin secretion rate are either likely to reflect the 
need for higher insulin secretion to remain non-diabetic given a primary effect on insulin 
resistance (e.g. HMGA2) or insulin processing (e.g. PCSK1), or need further data to support 
the findings. 
Alleles with disproportionate effects on different traits. 
We compared the effects of known variants across different traits (Fig. 1-4). Previous studies 
have highlighted that some known type 2 diabetes variants appear to have disproportionately 
small or large effects on type 2 diabetes risk compared to their effects on fasting glucose or 
insulin secretion (2). Here we highlight how measures of first phase insulin secretion help 
refine these comparisons. Several variants are noteworthy. First, our most notable finding is 
that of the common variant 6kb upstream of PDX1 which is the third most strongly associated 
locus with first phase insulin secretion (peak insulin) but there is no evidence it affects type 2 
diabetes risk even in the latest very large type 2 diabetes case control study (40). Unlike the 
alleles in or near G6PC2 and GRB10, the allele at PDX1 associated with lower insulin 
secretion and was also associated with higher fasting glucose. Second, the common variant in 
TCF7L2 appears to have a disproportionately small effect on first phase insulin secretion in 
response to IV glucose given its effect on type 2 diabetes and in comparison to other variants. 
This observation is consistent with the effect of this variant on OGTT-based measures of 
insulin secretion (2). There is emerging evidence that TCF7L2 influences diabetes risk 
through mechanisms involving multiple tissues (49-52), including a possible role on hepatic 
glucose production (53) in addition to direct effects at the pancreatic beta-cell (49; 52). One 
possibility is that the TCF7L2 risk allele also affects insulin clearance, a possibility consistent 
with our observation that the allele has a weaker effect on insulin secretion rate, (that uses C-
peptide as the main measure of insulin secretion, and so excludes any effects on hepatic 
insulin clearance from the insulin secretion measure) than peak insulin response (Fig. 3 & 4). 
Another possibility is that the effect of the TCF7L2 risk allele on diabetes risk additionally 
depends on impaired incretin action (54; 55) and impaired proinsulin processing (56; 57), 
mechanisms not directly assessed in the present study. Third, our data are also consistent with 
previous data on OGTT-based measures that show the variant at MTN1RB has a 
disproportionately large effect on insulin secretion and fasting glucose levels compared to its 
effect on type 2 diabetes, possibly as a result of an additional effect on insulin action (58). 
 
Our study had several strengths and limitations. Although our sample size of ~5,500 subjects 
is modest relative to previous OGTT-based measures, we have used the largest sample size 
yet for an intravenous-based measure of insulin secretion. Furthermore, we have 
characterised the most recent catalogue of variants associated with type 2 diabetes and 
glycaemic traits.  
 
The limitations were that we had a mixed ancestry set of studies, although results in 
Europeans were very similar, suggesting that the known common variants have limited, if 
any, heterogeneous effects across different ethnic groups. Some of the associations we 
observed only reached nominal levels of statistical confidence, and further analyses are 
needed, ideally in even larger sample sizes, to characterize the approximately 50% of known 
variants with no clear mechanism.  
 
In conclusion, our study provides further insight into the mechanisms by which common 
genetic variation influences type 2 diabetes risk and glycaemic traits, and it further supports 
the notion that many established genetic variants for type 2 diabetes risk confer increased risk 
through an effect on beta-cell function. 
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Table 1. Type 2 diabetes risk alleles associated with lower first phase insulin response, AIR and or peak insulin (P<0.05), from a total of 76 
analysed. Betas represent per allele effects in standard deviations. Associations reaching Bonferroni equivalents of P<0.05 are emboldened. 
 
 
          Peak insulin Acute insulin response 
Locus OGTT/fasting* Lead SNP Chr† Position‡ Risk Allele Beta§ SE P-value Beta§ SE P-value 
MTNR1B HG (1,2) rs10830963 11 92,708,710 G -0.235 0.023 1.34E-24 -0.218 0.023 3.65E-21 
CDKAL1 BC (1,2) rs7756992 6 20,679,709 G -0.152 0.022 1.50E-12 -0.131 0.022 1.45E-09 
HNF1A UC (1,2) rs12427353 12 121,426,901 G -0.141 0.029 1.07E-06 -0.136 0.029 3.15E-06 
IGF2BP2 UC rs4402960 3 185,511,687 T -0.101 0.022 4.90E-06 -0.091 0.022 4.65E-05 
TCF7L2 BC (1) rs7903146 10 114,758,349 T -0.105 0.024 7.39E-06 -0.103 0.024 1.43E-05 
ARAP1 (CENTD2) PROINS (2) rs1552224 11 72,433,098 A -0.128 0.030 1.92E-05 -0.140 0.030 3.54E-06 
SLC30A8 BC (1) rs3802177 8 118,185,025 G -0.089 0.022 5.88E-05 -0.090 0.022 5.94E-05 
ADCY5 BC (2) rs11717195 3 123,082,398 T -0.092 0.023 8.43E-05 -0.078 0.023 8.33E-04 
KCNQ1 UC (1,2) rs163184 11 2,847,069 G -0.075 0.020 1.52E-04 -0.082 0.020 3.73E-05 
C2CD4A N/A (1,2) rs7163757 15 62,391,608 C -0.072 0.022 8.05E-04 -0.071 0.022 9.34E-04 
HHEX/IDE BC (1) rs1111875 10 94,462,882 C -0.061 0.020 0.003 -0.058 0.020 0.005 
CDKN2A/B BC (1) rs10811661 9 22,134,094 T -0.087 0.029 0.003 -0.102 0.030 6.00E-04 
FAF1 N/A rs17106184 1 50,909,985 G -0.104 0.039 0.008 -0.091 0.039 0.020 
PTPRD N/A (1) rs17584499 9 8,879,118 T -0.063 0.027 0.020 -0.062 0.027 0.023 
PROX1 BC rs2075423 1 214,154,719 G -0.050 0.022 0.021 -0.060 0.022 0.006 
AP3S2 N/A (2) rs2028299 15 90,374,257 C -0.057 0.026 0.026 -0.052 0.026 0.045 
HNF1B UC (1) rs4430796 17 36,098,040 G -0.045 0.022 0.039 -0.066 0.022 0.003 
MAEA N/A (2) rs6815464 4 1,309,901 C -0.059 0.031 0.060 -0.063 0.031 0.043 
KCNK16 N/A rs1535500 6 39,284,050 T -0.041 0.022 0.060 -0.045 0.022 0.041 
DGKB BC rs17168486 7 14,898,282 T -0.044 0.024 0.061 -0.050 0.024 0.034 
LPP N/A rs6808574 3 187,740,523 C -0.039 0.023 0.090 -0.048 0.023 0.040 
*Association (P<0.05) with OGTT based measure of insulin secretion or fasting glucose, as reported by (1) Prokopenko et al (CIR), (2) this study (CIRBMI+SI adjusted) and as 
Dimas et al classified: HG=hyperglycemic, BC=beta cell ,UC=unclassified, N/A=not available in Dimas et al; indicated according to their classification HG: 
hyperglycaemic reduced beta-cell function after glucose stimulation, BC: defective beta-cell function, PROINS: decreased proinsulin, UC: unclassified. †Chromosome. 
‡Base-pair position build-37. §Betas represent standard deviation effects per risk allele. 
 
  
Table 2. Fasting glucose raising alleles associated with lower first phase insulin response but not identified as a type 2 diabetes risk allele. Betas 
represent per allele effects in standard deviations. Associations reaching Bonferroni equivalents of P<0.05 are emboldened. 
          Peak insulin Acute insulin response 
Locus Lead SNP Chr* Position† Effect Allele Beta‡ SE P-value Beta‡ SE P-value 
PDX1 rs11619319 13 28,487,599 G -0.106 0.023 2.54E-06 -0.115 0.023 3.74E-07 
DNLZ rs3829109 9 139,256,766 G -0.088 0.022 5.77E-05 -0.089 0.022 4.83E-05 
CRY2 rs11607883 11 45,839,709 G -0.047 0.020 0.017 -0.055 0.020 0.005 
GLIS3 rs10814916 9 4,293,150 C -0.044 0.020 0.029 -0.046 0.020 0.023 
PROX1 rs340874 1 214,159,256 C -0.041 0.020 0.039 -0.056 0.020 0.006 
ADRA2A rs11195502 10 113,039,667 C -0.069 0.035 0.052 -0.079 0.036 0.026 
*Chromosome. †Base-pair position build-37. ‡Betas represent standard deviation effects per risk allele. 
 
  
Table 3. Known type 2 diabetes and glycaemic trait variants associated with insulin secretion rate (ISR). N = 1,268. Betas represent per allele 
effects in standard deviations. Associations reaching Bonferroni equivalents of P<0.05 are emboldened. 
                ISR 
Locus Trait* Classification† 
Association 
Pattern‡ 
Lead SNP Chr§ Position|| Risk Allele Beta¶ SE P-value 
MTNR1B T2D / FG HG 1,2,3,4 rs10830963 11 92,708,710 G -0.232 0.043 9.01E-08 
CDKAL1 T2D / FG BC 1,2,3,4 rs7756992 6 20,679,709 G -0.232 0.045 1.91E-07 
CDKN2A/B T2D / FG BC 1,2,3 rs10811661 9 22,134,094 T -0.224 0.054 3.46E-05 
WFS1 T2D UC 
 
rs4458523 4 6,289,986 G -0.124 0.041 0.003 
SLC30A8 T2D / FG BC 1,2,3 rs3802177 8 118,185,025 G -0.122 0.044 0.006 
TMPRSS6 HbA1C N/A 
 
rs855791 22 37,462,936 A -0.114 0.042 0.006 
PDX1 FG N/A 1,2,4 rs11619319 13 28,487,599 G -0.129 0.049 0.008 
ANK1 T2D N/A 3 rs516946 8 41,519,248 C -0.113 0.048 0.018 
HHEX/IDE T2D BC 1,2,3 rs1111875 10 94,462,882 C -0.086 0.041 0.037 
IGF2BP2 T2D / FG UC 1,2 rs4402960 3 185,511,687 T -0.091 0.044 0.037 
*Associated trait: T2D=type 2 diabetes, FG=fasting glucose; †Classification by Dimas et al: HG=hyperglycemic, BC=beta cell ,UC=unclassified, N/A=not available 
in Dimas et al; ‡Code relating to significance of association across phenotypes and datasets: 1=associated at P<0.05 with peak insulin in our data, 2=associated at 
P<0.05 with acute insulin response in our data, 3=associated with CIR in Prokopenko et al., 4=associated at P<0.05 with CIRBMI+SI adjustment in our data. 
§Chromosome. ||Base-pair position build-37; ¶Betas represent standard deviation effects per effect allele. 
Table 4. Apparently paradoxical associations between known glycaemic variants and first phase insulin secretion. Betas represent per allele 
effects in standard deviations. Associations reaching Bonferroni equivalents of P<0.05 are emboldened. 
            Peak insulin Acute insulin response DI¶ 
Locus Known 
Trait* 
Lead SNP Chr† Position‡ Effect  
Allele 
Beta§ SE P-value P-value 
(BMI+SI)|| 
Beta§ SE P-value P-value 
(BMI+SI)|| 
P-value 
(BMI) 
G6PC2 FG rs560887 2 169,763,148 C 0.061 0.024 0.012 6.70E-04 0.074 0.024 0.002 8.25E-05 1.1E-04 
GRB10 FG rs6943153 7 50,791,579 T 0.069 0.021 8.47E-04 0.003 0.066 0.021 0.002 0.003 0.018 
OR4S1/PTPRJ# FG rs1483121 11 48,333,360 G 0.114 0.036 0.002 0.001 0.111 0.036 0.002 0.002 0.033 
MADD  Fproinsulin rs10501320 11 47,293,799 G 0.084 0.029 0.003 4.12E-04 0.090 0.029 0.002 4.82E-04 0.252 
PCSK1  Fproinsulin rs6235 5 95,728,898 G 0.096 0.025 1.09E-04 0.002 0.104 0.025 2.98E-05 4.35E-04 0.013 
PPARG FI-adjBMI rs17036328 3 12,390,484 T 0.096 0.029 9.42E-04 0.012 0.110 0.029 1.64E-04 0.005 0.302 
ARAP1 Fproinsulin rs11603334 11 72,432,985 A 0.128 0.030 1.96E-05 8.55E-04 0.140 0.030 3.60E-06 7.45E-05 0.027 
FTO BMI rs1421085 16 53,800,954 C 0.038 0.022 0.084 0.688 0.048 0.022 0.031 0.951 0.253 
GCC1 T2D rs6467136 7 127,164,958 G 0.052 0.022 0.015 0.024 0.050 0.022 0.021 0.033 0.068 
NOTCH2 T2D rs10923931 1 120,517,959 T 0.066 0.032 0.039 0.057 0.053 0.032 0.1 0.212 0.272 
*Trait previously associated with SNP. †Chromosome. ‡Base-pair position build-37. §Betas represent standard deviation effects per effect allele.||P-value after BMI+SI adjustment.  
FG=fasting glucose, Fproinsulin=fasting proinsulin,T2D=type 2 diabetes, FI-adjBMI=fasting insulin adjusted for BMI  ¶DI = Disposition Index adjusted for BMI; #PTPRJ is the nearest 
non-olfactory receptor gene in the locus. 
Table 5. Apparently paradoxical associations between known glycaemic variants and insulin secretion rate. Betas represent per allele effects in 
standard deviations. 
                ISR DI 
Locus Trait* Classification† 
Association 
Pattern‡ Lead SNP Chr§ Position|| 
Risk  
Allele Beta¶ SE P-value 
P-value  
(BMI)# 
P-value 
(BMI)#  
GRB10 FG N/A 3 rs6943153 7 50,791,579 T 0.143 0.045 0.001 8.25E-04 0.018 
HMG20A T2D N/A 
 
rs7178572 15 77,747,190 G 0.136 0.043 0.001 0.002 0.969 
OR4S1/PTPRJ FG N/A  rs1483121 11 48,333,360 G 0.232 0.086 0.007 0.003 0.033 
PCSK1  Fproinsulin N/A 
 
rs6235 5 95,728,898 G 0.108 0.044 0.015 0.02 0.013 
TMEM163 T2D N/A 2 rs6723108 2 135,479,980 T 0.094 0.042 0.024 0.03 0.854 
ADAMTS9 T2D UC 
 
rs6795735 3 64,705,365 C 0.088 0.040 0.028 0.02 0.428 
IKBKAP FG N/A 
 
rs16913693 9 111,680,359 T 0.246 0.117 0.036 0.05 0.404 
KLHDC5 T2D N/A 
 
rs10842994 12 27,965,150 C 0.104 0.050 0.038 0.04 0.291 
TET2 FI N/A 
 
rs9884482 4 106,081,636 C 0.082 0.041 0.048 0.03 0.788 
*Associated trait: FG=fasting glucose,Fproinsulin=fasting proinsulin,T2D=type 2 diabetes, FG=fasting glucose,FI=fasting insulin; †Classification by Dimas et al: 
UC=unclassified, N/A=not available; ‡Code relating to significance of association across phenotypes and datasets: 1=associated at P<0.05 with peak insulin in our data, 
2=associated at P<0.05 with acute insulin response in our data, 3=associated with CIR in Prokopenko et al., 4=associated at P<0.05 with CIRBMI+SI adj in our data. 
§Chromosome. ||Base-pair position build-37. ¶Betas represent standard deviation effects per effect allele; #P-value after ISR adjustment for BMI.  
FIGURE LEGENDS 
 
Figure 1. IVGTT (peak insulin response) based first phase insulin secretion versus OGTT 
based insulin secretion (corrected insulin response) for known type 2 diabetes variants. Units 
= standard deviation. Orange circles = SNP associated with both peak insulin response and 
CIR (P<0.05); green circles = SNP associated with peak insulin response (P<0.05); blue 
circles = SNP associated with CIR (P<0.05), yellow circles = SNP not associated with either 
trait (P>0.05). 
 
Figure 2. Insulin secretion rate versus OGTT based insulin secretion (corrected insulin 
response) for known type 2 diabetes variants. Units = standard deviation. Orange circles = 
SNP associated with both ISR and CIR (P<0.05); green circles = SNP associated with ISR 
(P<0.05); blue circles = SNP associated with CIR (P<0.05), yellow circles = SNP not 
associated with either trait (P>0.05). 
 
Figure 3. IVGTT (peak insulin response) based first phase insulin secretion versus type 2 
diabetes risk (OR = Odds ratio), for known type 2 diabetes variants. Y-axis units = standard 
deviation. (Type 2 diabetes odds ratios are from Morris et al(39), and some were reported 
from previous studies of East Asians(59; 60). Orange circles = SNP associated with both 
peak insulin response and type 2 diabetes risk (P<0.05); green circles = SNP associated with 
peak insulin response (P<0.05); blue circles = SNP associated with type 2 diabetes risk 
(P<0.05), yellow circles = SNP not associated with either trait (P>0.05). 
 
Figure 4. Insulin secretion rate versus type 2 diabetes risk for known type 2 diabetes variants. 
Y-axis units = standard deviation. Orange circles = SNP associated with both ISR and type 2 
diabetes risk (P<0.05); green circles = SNP associated with ISR (P<0.05); blue circles = SNP 
associated with type 2 diabetes risk (P<0.05), yellow circles = SNP not associated with either 
trait (P>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
